期刊
TRANSPLANTATION AND CELLULAR THERAPY
卷 28, 期 6, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtct.2022.03.023
关键词
Adoptive immunotherapy; Cancer; Chimeric antigen receptor; Cognition; Quality of life
资金
- National Institutes of Health [K23 CA201594, P30 CA076292]
- 2017 Moffitt Team Science Award
- Participant Research, Interventions, and Measurement (PRISM) Core Facility at the Moffitt Cancer Center & Research Institute
- Moffitt's Cancer Center Support Grant [P30-CA076292]
This study examined changes in neurocognitive performance in adult CAR T cell therapy recipients in the first year after treatment for non-Hodgkin lymphoma (NHL). The results showed a slight decline in total neurocognitive performance and executive function, as well as a small but significant linear decline in visuospatial ability over time. Patients with more previous therapy lines and worse neurotoxicity demonstrated worse neurocognitive performance.
The success of chimeric antigen receptor (CAR) T cell therapy in treating patients with relapsed/refractory hematologic malignancies is leading to a growing number of survivors treated with this regimen. To our knowledge, no previous studies have examined neurocognitive performance in adult CAR T cell therapy recipients, despite high rates of neurotoxicity and cytokine release syndrome (CRS) in the acute treatment period. This study examined changes in neurocognitive performance in the first year after CAR T cell therapy for non-Hodgkin lymphoma (NHL). Putative risk factors for worsening neurocognitive performance (eg, neurotoxicity, CRS) were explored as well. Neurocognition was assessed before initiation of CAR T cell therapy and at 30, 90, and 360 days post-treatment. Clinical variables were abstracted from medical records. Mixed models were used to examine change in total neurocognitive performance (TNP) and cognitive domains (ie, attention, executive function, verbal ability, immediate and delayed memory, and visuospatial abilities). Among 117 participants (mean age, 61 years; 62% male), TNP and executive function declined slightly on average from baseline to day 90 and then improved from day 90 to day 360 (P <.04). Small but significant linear declines in visuospatial ability on average were also observed over time (P =.03). Patients who had 4 or more lines of previous therapy and those with worse neurotoxicity (but not CRS) demonstrated worse TNP. CAR T cell therapy recipients reported transient or persistent deterioration in several cognitive domains, although changes were slight. These findings may be useful when educating future patients on what to expect when receiving CAR T cell therapy. (c) 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据